Here’s Why Analysts Have IDEXX Stock Priced at $742
IDEXX Laboratories (IDXX) is viewed by analysts with a mean price target of $742.54, implying significant upside, despite a projected decline in U.S. clinical visits. The company is experiencing strong growth through new product cycles, including the inVue Dx analyzer and Cancer Dx tests, contributing to recurring revenue and expanding operating margins. With a robust pipeline and consistent share buybacks, IDXX appears undervalued based on its durable recurring revenue and accelerating diagnostic frequency.
William Blair Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating
William Blair has reiterated its Buy rating on IDEXX Laboratories Inc (IDXX.US). This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
IDEXX Laboratories Inc. shares rose by 1.39% to $577.44, extending its winning streak to four consecutive days. This strong performance occurred on a positive trading day where the S&P 500 Index increased by 0.44% and the Dow Jones Industrial Average rose by 0.36%. The article highlights IDEXX's outperformance compared to the broader market.
IVF In Animals Market Generated Opportunities, Future Scope
Coherent Market Insights has published a report titled "IVF In Animals Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033". The report details market competition, geographic distribution, growth potential, industry performance, and key success factors. Leading players include Zoetis, Merck Animal Health, and Elanco Animal Health, with segmentation covering various animal types.
Neogen Leadership Change Puts Governance And Compliance Execution In Focus
Neogen (NasdaqGS:NEOG) has announced the departure of its Chief Legal and Administrative Officer, Amy Rocklin, effective March 31, 2026. This leadership change is significant due to Neogen's recent performance fluctuations and ongoing issues like labor actions and product quality concerns. Investors are advised to monitor the company's succession plan, shifts in compliance priorities, and how the board communicates around this transition, especially given the company's current unprofitability and integration challenges.
Revvity, Inc. (RVTY) stock price, news, quote and history
This Yahoo Finance page provides comprehensive financial information for Revvity, Inc. (RVTY), including its current stock price, dividend announcements, historical performance data, and key metrics. It also offers an overview of the company's health sciences solutions, its market position in diagnostics and research, and analyst insights. The page enables users to compare RVTY with similar companies in the Diagnostics & Research industry.
IDEXX Laboratories Now Offers Cancer Testing Features for Dogs in the UK
IDEXX Laboratories has launched its Cancer Dx Panel in the UK, initially offering early detection of lymphoma in at-risk dogs. The blood test can be integrated into regular wellness screenings and diagnostic workflows, providing results within 3-5 business days. This initiative addresses the high incidence of cancer in dogs and meets the strong demand from UK pet owners for proactive cancer screening.
IDEXX Reveals Q2 Earnings Date and Major Investor Day Event: Key Details Inside
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has scheduled the release of its 2025 second quarter financial results for Monday, August 4, 2025, before the market opens, followed by an analyst conference call. Additionally, the company will host its 2025 Investor Day on Thursday, August 14, 2025, at its corporate headquarters in Westbrook, Maine, with a live webcast available for both events on its investor relations website. These events will provide insights into the company's financial performance and future strategies in pet healthcare innovation.
Three Seasons Wealth LLC Has $1.55 Million Stake in IDEXX Laboratories, Inc. $IDXX
Three Seasons Wealth LLC significantly reduced its stake in IDEXX Laboratories (IDXX) by 55.4% in the fourth quarter, now holding 2,284 shares valued at $1.55 million. Despite this, IDEXX reported strong Q4 earnings, beating estimates with $3.08 EPS and $1.09 billion in revenue, and set an optimistic FY2026 guidance. Analysts currently rate the stock as a "Moderate Buy" with an average price target of $772.22, though some have lowered their targets, while company insiders have been net sellers, disposing of over $29 million worth of shares.
Nisa Investment Advisors LLC Has $29.41 Million Holdings in IDEXX Laboratories, Inc. $IDXX
Nisa Investment Advisors LLC increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.6% in the fourth quarter, now holding 43,469 shares valued at $29.41 million. Despite insider selling totaling $29.86 million over the last 90 days and recent analyst price target cuts, IDEXX Laboratories maintains a "Moderate Buy" consensus rating with an average target price of $772.22. The company reported strong Q4 earnings, surpassing analyst estimates, and projects robust FY 2026 guidance.
IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma
IDEXX has announced the availability of its Cancer Dx Panel in the UK, designed for the early detection of canine lymphoma. This veterinary diagnostic tool aims to improve the management and treatment of cancer in dogs by enabling earlier identification of the disease. The announcement highlights a focus on enhancing pet health through advanced diagnostic solutions.
IDEXX Laboratories, Inc.: IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma
IDEXX Laboratories has launched its Cancer Dx Panel in the UK, offering early detection of lymphoma in at-risk dogs. This blood test can be integrated into regular wellness screenings and diagnostic panels, with results available within 3-5 business days. The panel boasts high accuracy, provides actionable next steps, and has shown promise in monitoring treatment responses for canine lymphoma.
IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma
IDEXX Laboratories, Inc. has launched its Cancer Dx Panel in the United Kingdom, specifically for the early detection of lymphoma in at-risk dogs. This blood test, available for integration into wellness screenings, provides results within 3–5 business days and aims to help veterinarians identify cancer up to eight months before clinical signs appear. Cancer remains a leading cause of canine death, and this panel seeks to improve outcomes through earlier intervention and comprehensive support from IDEXX Medical Consultants.
Stifel Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Cuts Target Price to $675
Stifel analyst Jonathan Block has reiterated a Buy rating for IDEXX Laboratories Inc (IDXX.US) but has reduced the target price from $775 to $675. This adjustment comes despite the maintained Buy rating, reflecting a change in the analyst's valuation of the company. Block's past performance shows a 47.5% success rate and a 4.6% average return over the last year, according to TipRanks data.
Veterinary Diagnostic Imaging Market Report 2026: Siemens Healthineers, General Electric, and Fujifilm Lead the $2.55 Billion Industry
The veterinary diagnostic imaging market is experiencing robust growth, projected to expand from $2.37 billion in 2025 to $2.55 billion in 2026, and is expected to reach $3.39 billion by 2030. Key drivers include increased pet ownership, demand for advanced veterinary care, and technological advancements like AI-assisted imaging and cloud-based systems. Major players such as Siemens Healthineers, General Electric, and Fujifilm are leading this growth, with significant activity in North America and anticipated rapid growth in Asia-Pacific.
Veterinary Diagnostic Imaging Market Report 2026: Siemens Healthineers, General Electric, and Fujifilm Lead the $2.55 Billion Industry
The veterinary diagnostic imaging market is projected to grow from $2.37 billion in 2025 to $2.55 billion in 2026, with an anticipated rise to $3.39 billion by 2030, driven by increased pet ownership, advanced care demand, and AI integration. Key opportunities include AI-assisted imaging, cloud-based systems, and expanding infrastructure. Siemens Healthineers, General Electric, and Fujifilm Holdings Corporation are leading companies in this sector, with North America leading the market in 2025 and Asia-Pacific expected to be the fastest-growing region.
Companion Animal Health Market Forecast 2026-2033 Featuring Strategic Analysis of Agrolabo, Boehringer Ingelheim, Ceva, Elanco, IDEXX Labs and More
The global companion animal health market is projected to grow from USD 25.46 billion in 2025 to USD 56.41 billion by 2033, exhibiting a CAGR of 10.6%. This growth is attributed to advancements in therapeutics and diagnostics, increased awareness of zoonotic diseases, and evolving regulatory frameworks. The report provides a comprehensive analysis including market segmentation by animal, product, distribution channel, and end-use, alongside profiles of key industry players.
Food Testing Kits Market Is Going to Boom | Thermo Fisher Scientific • Eurofins Scientific • SGS SA
A new report by Coherent Market Insights analyzes the Food Testing Kits Market, projecting substantial growth from 2026 to 2033. The report covers market trends, drivers, challenges, and the competitive landscape, highlighting key players, technological innovations, and investment potential. It provides a comprehensive segmentation including product types, applications, end-user markets, and geographical regions, aimed at empowering businesses with actionable insights for strategic decision-making.
IDEXX Laboratories, Inc. $IDXX Shares Acquired by Beacon Investment Advisory Services Inc.
Beacon Investment Advisory Services Inc. has increased its stake in IDEXX Laboratories (IDXX) by 11.9%, now holding 62,951 shares valued at approximately $42.6 million. This makes IDEXX its 15th largest holding, representing about 1.7% of its portfolio. The company recently exceeded Q4 earnings expectations with $3.08 EPS and $1.09 billion revenue, and it set optimistic FY2026 guidance, while institutional investors collectively own 87.84% of its stock.
DAVENPORT & Co LLC Sells 1,857 Shares of IDEXX Laboratories, Inc. $IDXX
DAVENPORT & Co LLC reduced its stake in IDEXX Laboratories, Inc. by 35.8% in the fourth quarter, selling 1,857 shares and now holding 3,333 shares worth $2.255 million. This comes as IDEXX reported strong Q4 results, beating EPS and revenue expectations, and provided optimistic FY2026 guidance. Despite positive earnings, recent insider activity shows a net selling trend, with 45,957 shares disposed of by insiders in the last 90 days.
DAVENPORT & Co LLC Reduces IDEXX Laboratories Stake
Institutional investor DAVENPORT & Co LLC has reduced its stake in IDEXX Laboratories (NASDAQ:IDXX) by 35.8% during the fourth quarter, selling 1,857 shares. This move leaves the firm with 3,333 shares valued at $2.25 million, reflecting a cautious stance due to the stock's recent volatility and broader market conditions. IDEXX Laboratories is a key supplier of diagnostic tools and services for animal health, and investors are now keenly awaiting its upcoming earnings report.
IDXX (IDEXX Laboratories) Net Issuance of Preferred Stock : $0 Mil (TTM As of Dec. 2025)
IDEXX Laboratories (IDXX) reported a Net Issuance of Preferred Stock of $0 Million for the trailing twelve months (TTM) as of December 2025. This metric indicates that the company neither significantly issued new preferred shares nor repurchased existing ones during this period. According to GuruFocus, IDEXX Laboratories has a strong GF Score of 99/100 and is considered modestly undervalued, with a GF Value of $622.07 against a current price of $558.32, although one warning sign is noted for investors to review.
[ARS] IDEXX LABORATORIES INC /DE SEC Filing
This article reports on an ARS (Annual Report to Security Holders) SEC filing by IDEXX LABORATORIES INC /DE (IDXX) on March 27, 2026, at 04:01 PM. The filing is categorized with low impact and neutral sentiment. The article also provides a brief overview of IDEXX, including its market capitalization, industry, and recent news and SEC filings.
IDEXX Laboratories Inc. stock underperforms Friday when compared to competitors
IDEXX Laboratories Inc. (IDXX) shares fell by 2.61% on Friday, closing at $558.32, amidst a general market decline with the S&P 500 and Dow Jones Industrial Average also experiencing losses. This marks the second consecutive day of losses for the stock.
Vanguard disaggregates holdings; IDEXX (NASDAQ: IDXX) shows zero
The Vanguard Group has filed an amended Schedule 13G/A for IDEXX Laboratories Inc (NASDAQ: IDXX), reporting zero beneficial ownership of common stock. This change is a result of an internal realignment initiated on January 12, 2026, which disaggregated reporting responsibilities among Vanguard's subsidiaries. These subsidiaries will now report their beneficial ownership separately, in accordance with SEC Release No. 34-39538.
IDEXX Laboratories, Inc. $IDXX Shares Acquired by Global X Japan Co. Ltd.
Global X Japan Co. Ltd. significantly increased its stake in IDEXX Laboratories, Inc. by 395.9% in Q4, holding 3,516 shares valued at approximately $2.38 million. IDEXX Laboratories exceeded quarterly expectations with $3.08 EPS and $1.09 billion in revenue, and provided FY2026 EPS guidance of 14.29–14.80. Despite insider selling activity, institutional investors maintain a strong interest in the company.
Riverbridge Partners LLC Sells 5,734 Shares of IDEXX Laboratories, Inc. $IDXX
Riverbridge Partners LLC has reduced its stake in IDEXX Laboratories (NASDAQ:IDXX) by 6.0%, selling 5,734 shares. Despite this sale, IDEXX remains the 27th largest holding for Riverbridge, representing about 1.1% of its portfolio. The company recently surpassed Q4 earnings estimates and provided optimistic FY2026 guidance, though some analysts have revised price targets downwards to "neutral."
Nordea Investment Management AB Boosts Stock Position in IDEXX Laboratories, Inc. $IDXX
Nordea Investment Management AB significantly increased its stake in IDEXX Laboratories (NASDAQ:IDXX) by 114.1% in Q4, now holding 16,597 shares valued at $11.28 million. Despite this institutional confidence, key insiders, including CEO Jonathan Jay Mazelsky, have recently sold a substantial number of shares, indicating a 21.81% reduction in the CEO's ownership. Analysts generally rate IDEXX as a "Moderate Buy" with an average price target of $783.33, even as some have trimmed their targets.
Idexx Laboratories announces executive departure and separation agreement
Idexx Laboratories (NASDAQ:IDXX) announced that Nimrata Hunt, Executive Vice President, Global Strategy and Commercial, will depart the company effective April 13, with advisory services until July 13. Her separation is deemed "without cause," entitling her to significant benefits including salary continuation for 104 weeks, totaling $1.23 million, and two years' target annual bonus amounting to $984,000. This transition occurs amidst mixed analyst sentiments and recent financial results, including exceeded revenue but a slight EPS miss in Q4.
Latest PAWZ ETF News Today | Earnings, Events & Price Alerts
This page provides the latest news, earnings, events, and price alerts for the PAWZ ETF. It features a collection of recent articles related to pet care companies like Chewy, Zoetis, Petco Health, and Freshpet, discussing topics such as e-commerce trends, AI initiatives, stock performance, and analyst ratings. The content aims to keep investors informed on the pet care sector.
IDEXX: Nimrata Hunt to Leave EVP Role, Will Serve as Advisor Through July 13, 2026
Nimrata Hunt will transition from her Executive Vice President role at IDEXX on April 13, 2026, continuing as an advisor until July 13, 2026. Her departure is due to position elimination, and she will receive significant separation benefits. Unvested equity awards will be forfeited, while vested options remain exercisable.
IDEXX Laboratories (NASDAQ: IDXX) executive Nimrata Hunt plans exit with package
IDEXX Laboratories (NASDAQ: IDXX) announced that Executive Vice President, Global Strategy and Commercial, Nimrata Hunt, PhD, will depart her role on April 13, 2026, and serve as a special advisor until July 13, 2026. The company is providing a separation package totaling over $2.2 million in salary and bonuses, along with other benefits, classifying her departure as a termination without cause due to position elimination. All unvested equity awards will be forfeited, while vested options remain exercisable under existing terms.
IDEXX Laboratories Experiences Revision in Stock Evaluation Amid Strong Market Performance
IDEXX Laboratories, Inc. has undergone a revised stock evaluation showing a slight price increase and significant outperformance against the S&P 500 over the past year and decade. Technical indicators present a mixed outlook, with both bullish and bearish signals across different measurements. The company's resilience and strong market position are highlighted by its long-term returns.
IDXX (IDEXX Laboratories) Cash Flow from Investing : $-136 Mil (TTM As of Dec. 2025)
IDEXX Laboratories (IDXX) reported a Cash Flow from Investing of $-136 million for the trailing twelve months as of December 2025. This figure represents the cash spent on investment activities such as purchasing property, plant, equipment, and investments, offset by cash gained from selling investments. Despite this, GuruFocus rates IDXX with a GF Score™ of 99/100 and considers the stock "Fairly Valued," although it notes one warning sign for investors to review.
Assenagon Asset Management S.A. Acquires 19,741 Shares of IDEXX Laboratories, Inc. $IDXX
Assenagon Asset Management S.A. has increased its stake in IDEXX Laboratories, Inc. by 35.3%, acquiring an additional 19,741 shares, bringing its total holdings to 75,609 shares valued at $51.15 million. This move comes amidst other institutional investors also adjusting their positions in IDEXX, and a consensus "Moderate Buy" rating from analysts with an average target price of $783.33. Recent insider transactions show executives selling shares, while the company reported Q4 earnings slightly below expectations but with strong revenue growth.
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors
IDEXX Laboratories Inc. (IDXX) stock fell by 1.43% on Tuesday, closing at $570.21, as the broader market also experienced a downturn. This performance left the company 25.94% below its 52-week high of $769.98. The S&P 500 and Dow Jones Industrial Average also registered losses during the trading session.
UBS Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Maintains Target Price $730
UBS analyst Andrea Alfonso has reiterated a Hold rating for IDEXX Laboratories Inc (IDXX.US) and maintained a target price of $730. According to TipRanks, the analyst boasts a 70.0% success rate and an average return of 32.3% over the past year. The report emphasizes that this information is for informational purposes only and not investment advice.
UBS Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Maintains Target Price $730
UBS has maintained its Hold rating on IDEXX Laboratories Inc (IDXX.US) and kept its target price at $730. This indicates the firm's continued neutral stance on the company's stock with a specific price expectation.
Marshall Financial Group LLC Sells 1,936 Shares of IDEXX Laboratories, Inc. $IDXX
Marshall Financial Group LLC significantly reduced its stake in IDEXX Laboratories, selling 1,936 shares and bringing its total holdings to 483 shares worth $327,000. Company insiders also conducted substantial sales, totaling over $29 million, while analysts maintain a "Moderate Buy" rating with an average target of $783.33 for the stock. Despite a slight EPS miss, IDEXX Laboratories reported increased revenue and provided positive FY2026 EPS guidance.
Seilern Investment Management Ltd Decreases Stake in IDEXX Laboratories, Inc. $IDXX
Seilern Investment Management Ltd significantly reduced its stake in IDEXX Laboratories, Inc. by 28.7% in Q4, now holding 100,790 shares valued at $68.19 million, representing 5.3% of its portfolio. This reduction comes amid substantial insider selling by company executives, including CEO Jonathan Mazelsky, who sold 23,326 shares. Despite the institutional selling, IDEXX Laboratories reported increased revenues and analysts maintain a "Moderate Buy" consensus rating with a target price of $783.33.
Procyon Advisors LLC Buys Shares of 2,905 IDEXX Laboratories, Inc. $IDXX
Procyon Advisors LLC recently acquired 2,905 shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the fourth quarter, a new stake valued at approximately $1.97 million. This move comes amidst significant insider selling totaling some $29.86 million, while institutional investors collectively own 87.84% of the stock. Despite a consensus "Moderate Buy" rating from analysts with an average price target of $783.33, the company recently reported a slight EPS miss for the quarter and analysts have trimmed price targets.
Pricier vet care: Fewer visits but still many $11,000 surgeries
Despite a decline in routine vet visits, pet owners are still spending significant amounts on emergency and critical care for their animals, leading to continued growth in animal health companies' earnings. This trend is attributed to the increasing humanization of pets, where owners view them as family members and are willing to incur high costs for their well-being, even for surgeries costing thousands of dollars. Companies like IDEXX Laboratories, Zoetis Inc., Elanco Animal Health Inc., Petco Health & Wellness Co., and Chewy Inc. are benefiting from this consistent spending on premium pet care.
IDEXX Stock Fell 14% in 2026. Here’s Why $750 Target Mean Still Holds
IDEXX Laboratories (IDXX) stock fell 14% in 2026 despite strong Q4 revenue and exceeding targets for its inVue Dx cell cytology analyzer. Wall Street analysts maintain a mean price target of $750, implying a 30% upside, due to anticipated acceleration in recurring revenue from aging pandemic pets and the inVue Dx pull-through. The company's valuation models also suggest significant upside, driven by sustained recurring revenue growth and expansion in its Cancer Dx initiatives, despite market concerns about veterinary visit declines.
CIBC Bancorp USA Inc. Invests $8.93 Million in IDEXX Laboratories, Inc. $IDXX
CIBC Bancorp USA Inc. has acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by purchasing 13,983 shares valued at approximately $8.93 million during the third quarter. Other institutional investors have also adjusted their holdings in IDEXX, with the stock currently experiencing a slight dip. Analysts have a "Moderate Buy" consensus rating for IDXX, though recent price target reductions and a downgrade from one firm have been noted.
Swiss Life Asset Management Ltd Has $16.96 Million Holdings in IDEXX Laboratories, Inc. $IDXX
Swiss Life Asset Management Ltd increased its stake in IDEXX Laboratories, Inc. by 23.7%, valuing its holdings at $16.96 million. This comes despite significant insider selling, with CEO Jonathan Mazelsky selling shares worth $15.34 million and other insiders disposing of nearly $30 million in the past 90 days. Analysts maintain a "Moderate Buy" rating for IDEXX, with an average target price of $783.33, even after the company slightly missed its quarterly EPS estimates but saw a 14.3% increase in revenue.
There’s Still Hope for This Struggling Concentrated Growth Fund
Polen Growth (POLRX), a concentrated growth fund, has underperformed its benchmark and peers for several years due to market headwinds, portfolio concentration issues, and stock-picking errors, particularly missing out on high-flying tech stocks. Despite these struggles, the article argues that the fund's strong management team, disciplined investment process focusing on quality companies, and recent adjustments to their strategy offer hope for future improved performance.
IDEXX Laboratories Experiences Revision in Stock Evaluation Amid Mixed Technical Signals
IDEXX Laboratories has seen a stock price increase and a shift in its technical trend, with its current stock price at $586.37. Despite recent short-term challenges, the company has delivered strong long-term performance, outperforming the S&P 500 over the past year with a 41.19% return. Technical indicators show mixed signals, including bearish MACD weekly but bullish monthly, divergent RSI signals, and mixed Bollinger Bands, suggesting volatility and complex momentum.
Mirabella Financial Services LLP Buys 2,683 Shares of IDEXX Laboratories, Inc. $IDXX
Mirabella Financial Services LLP significantly increased its stake in IDEXX Laboratories, Inc. by 156.2% in the third quarter, purchasing an additional 2,683 shares. This increased their total holdings to 4,401 shares valued at $2.806 million. The article also notes other institutional investor activity, provides IDEXX's financial performance, and details recent analyst ratings and insider stock transactions.
Former Elanco director joins ImmuCell board in calf-health push
ImmuCell (Nasdaq: ICCC) has appointed Kathy Turner, a former director at Elanco Animal Health with over 30 years of global commercial leadership experience, to its Board of Directors, effective April 1, 2026. She will replace Steven Rosgen and chair the Compensation and Stock Option Committee while also serving on the Audit Committee. Turner's extensive background is expected to bolster ImmuCell's efforts to expand the reach of its First Defense® product line internationally.
ImmuCell (NASDAQ: ICCC) names Kathy Turner to Board as Rosgen retires
ImmuCell Corporation announced that Steven A. Rosgen is retiring from its Board of Directors effective April 1, 2026. Kathy V. Turner has been appointed to the Board to fill the vacancy, also effective April 1, 2026. Ms. Turner brings over three decades of commercial leadership experience in global healthcare and animal health, including senior roles at IDEXX Laboratories and Abbott Laboratories, and will chair the Compensation and Stock Option Committee while serving on the Audit Committee.
